What is he best known for?
The fields of study he is best known for:
- Cancer
- Gene
- Internal medicine
His main research concerns Melanoma, Cancer research, Internal medicine, Vemurafenib and Oncology.
The study incorporates disciplines such as Survival rate, V600E, Ipilimumab and Hazard ratio in addition to Melanoma.
His Cancer research research incorporates elements of Mutation, Carcinogenesis, Neuroblastoma RAS viral oncogene homolog, Cell cycle and PTEN.
His biological study spans a wide range of topics, including Gastroenterology and Surgery.
His research in Vemurafenib intersects with topics in Proto-Oncogene Proteins B-raf, Mutant and Drug resistance.
His studies deal with areas such as Clinical endpoint, Trametinib, Imatinib, Pharmacology and Immunotherapy as well as Oncology.
His most cited work include:
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation (5698 citations)
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (4552 citations)
- Inhibition of mutated, activated BRAF in metastatic melanoma. (2901 citations)
What are the main themes of his work throughout his whole career to date?
Melanoma, Cancer research, Internal medicine, Oncology and Vemurafenib are his primary areas of study.
His Melanoma research includes elements of Cancer, Targeted therapy, Immunology and Neuroblastoma RAS viral oncogene homolog.
His Cancer research study incorporates themes from Protein kinase B, Kinase, Cell cycle, PI3K/AKT/mTOR pathway and Transcription.
As part of his studies on Internal medicine, Grant A. McArthur often connects relevant areas like Surgery.
His Oncology research is multidisciplinary, relying on both Metastatic melanoma, Pathology, Placebo, Hazard ratio and Immunotherapy.
His work deals with themes such as V600E, MEK inhibitor and Dacarbazine, which intersect with Vemurafenib.
He most often published in these fields:
- Melanoma (61.76%)
- Cancer research (61.28%)
- Internal medicine (48.00%)
What were the highlights of his more recent work (between 2017-2021)?
- Melanoma (61.76%)
- Internal medicine (48.00%)
- Cancer research (61.28%)
In recent papers he was focusing on the following fields of study:
Grant A. McArthur mainly focuses on Melanoma, Internal medicine, Cancer research, Oncology and Vemurafenib.
Grant A. McArthur has researched Melanoma in several fields, including Cancer, Targeted therapy, Immunotherapy, MEK inhibitor and Neuroblastoma RAS viral oncogene homolog.
When carried out as part of a general Internal medicine research project, his work on Ipilimumab, Clinical trial, Cohort and Hazard ratio is frequently linked to work in In patient, therefore connecting diverse disciplines of study.
His Cancer research research integrates issues from Protein kinase B, Oncogene, Ribosome biogenesis, Translation and Transcription.
The Oncology study combines topics in areas such as Metastatic melanoma, Retrospective cohort study, Biomarker, Prospective cohort study and Adjuvant therapy.
His Vemurafenib research is multidisciplinary, incorporating perspectives in Randomized controlled trial, Survival analysis and Dacarbazine.
Between 2017 and 2021, his most popular works were:
- Oncogenic Signaling Pathways in The Cancer Genome Atlas (792 citations)
- Five-year survival with combined nivolumab and ipilimumab in advanced melanoma: New England Journal of Medicine (594 citations)
- Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study (352 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Gene
- Internal medicine
Grant A. McArthur mostly deals with Melanoma, Internal medicine, Cancer research, Oncology and Vemurafenib.
He studies Dabrafenib which is a part of Melanoma.
His Cancer research research incorporates themes from Oncogene, Cyclin-dependent kinase 6, Palbociclib and Cyclin-dependent kinase 4.
He has included themes like Systemic therapy and Adjuvant therapy in his Oncology study.
The concepts of his Vemurafenib study are interwoven with issues in MEK inhibitor and Medical imaging.
His Ipilimumab study combines topics in areas such as Nivolumab and Retrospective cohort study.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
